Combined detection of serum ul16-binding protein 2 and macrophage inhibitory cytokine-1 improves early diagnosis and prognostic prediction of pancreatic cancer

Oncology Letters

Volumn 8, Issue 5, 2014, Pages 2096-2102

  Zhou, Yu Fen ^a   Xu, Ling Xiao ^a   Huang, Li Ya ^b   Guo, Fang ^a   Zhang, Fan ^a   He, Xiang Yi ^a   Yuan, Yao Zong ^a   Yao, Wei Yan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

Macrophage inhibitory cytokine 1; Pancreatic cancer; Serum biomarker; UL16 binding protein 2

Indexed keywords

BIOLOGICAL MARKER; CA 19-9 ANTIGEN; GROWTH DIFFERENTIATION FACTOR 15; NATURAL KILLER CELL RECEPTOR NKG2D;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

EID: 84907148564     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2429     Document Type: Article

References (28)

1. Berrino F, De Angelis R, Sant M, et al; EUROCARE Working Group: Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 8: 773-783, 2007.
2. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
3. Ishikawa O, Ohigashi H, Imaoka S, et al: Minute carcinoma of the pancreas measuring 1 cm or less in diameter - collective review of Japanese case reports. Hepatogastroenterology 46: 8-15, 1999.
4. Yachida S, Jones S, Bozic I, et al: Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467: 1114-1117, 2010.
5. Pannala R, Basu A, Petersen GM and Chari ST: New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 10: 88-95, 2009.
6. Cosman D, Müllberg J, Sutherland CL, et al: ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14: 123-133, 2001.
7. Bootcov MR, Bauskin AR, Valenzuela SM, et al: MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci USA 94: 11514-11519, 1997.
8. Hruban RH, Maitra A, Kern SE and Goggins M: Precursors to pancreatic cancer. Gastroenterol Clin North Am 36: 831-849, 2007.
9. AJCC Cancer Staging Manual. 6th edition. Springer-Verlag, New York, NY, 2002.
10. Gui JC, Yan WL and Liu XD: CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis. Clin Exp Med 14: 225-233, 2014.
11. Wu E, Zhou S, Bhat K and Ma Q: CA 19-9 and pancreatic cancer. Clin Adv Hematol Oncol 11: 53-55, 2013.
12. Hartwig W, Strobel O, Hinz U, et al: CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol 20: 2188-2196, 2013.
13. Singh S, Tang SJ, Sreenarasimhaiah J, et al: The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Dig Dis Sci 56: 2491-2496, 2011.
14. Chang YT, Wu CC, Shyr YM, et al: Secretome-based identification of ULBP2 as a novel serum marker for pancreatic cancer detection. PLoS One 6: e20029, 2011.
15. Koopmann J, Buckhaults P, Brown DA, et al: Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 10: 2386-2392, 2004.
16. Koopmann J, Rosenzweig CN, Zhang Z, et al: Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 12: 442-446, 2006.
17. Yamaguchi K, Chikumi H, Shimizu A, et al: Diagnostic and prognostic impact of serum-soluble UL16-binding protein 2 in lung cancer patients. Cancer Sci 103: 1405-1413, 2012.
18. Bünger S, Laubert T, Roblick UJ and Habermann JK: Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Res Clin Oncol 137: 375-389, 2011.
19. Cerwenka A and Lanier LL: Natural killer cells, viruses and cancer. Nat Rev Immunol 1: 41-49, 2001.
20. Champsaur M and Lanier LL: Effect of NKG2D ligand expression on host immune responses. Immunol Rev 235: 267-285, 2010.
21. Li H, Lakshmikanth T, Garofalo C, et al: Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP 2. Cell Cycle 10: 3346-3358, 2011.
22. Brown DA, Hance KW, Rogers CJ, et al: Serum macrophage inhibitory cytokine-1 (MIC-1/GDF15): a potential screening tool for the prevention of colon cancer? Cancer Epidemiol Biomarkers Prev 21: 337-346, 2012.
23. Senapati S, Rachagani S, Chaudhary K, et al: Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK-RhoA signaling pathway. Oncogene 29: 1293-1302, 2010.
24. Chen SJ, Karan D, Johansson SL, et al: Prostate-derived factor as a paracrine and autocrine factor for the proliferation of androgen receptor-positive human prostate cancer cells. Prostate 67: 557-571, 2007.
25. Proutski I, Stevenson L, Allen WL, et al: Prostate-derived factor -a novel inhibitor of drug-induced cell death in colon cancer cells. Mol Cancer Ther 8: 2566-2574, 2009.
26. Tan M, Wang Y, Guan K and Sun Y: PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway. Proc Natl Acad Sci USA 97: 109-114, 2000.
27. Li PX, Wong J, Ayed A, et al: Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J Biol Chem 275: 20127-20135, 2000.
28. Johnen H, Lin S, Kuffner T, et al: Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat Med 13: 1333-1340, 2007.